Javier Fernández-Ruiz

Research Profile

Living Beings

Chemicals & Drugs

Anatomy

Activities & Behaviors

Motor Activity

Co-author Network

Publications

TOP 3
Eva de Lago; Miguel Moreno-Martet; Ana Cabranes; José A Ramos; Javier Fernández-Ruiz
Cannabinoids ameliorate disease progression in a model of multiple sclerosis in mice, acting preferentially through CB1 receptor-mediated anti-inflammatory effects.
Miguel Moreno-Martet; Leyre Mestre; Frida Loría; Carmen Guaza; Javier Fernández-Ruiz; Eva de Lago
Identification of receptors and enzymes for endocannabinoids in NSC-34 cells: relevance for in vitro studies with cannabinoids in motor neuron diseases.
Onintza Sagredo; M Ruth Pazos; Valentina Satta; José A Ramos; Roger G Pertwee; Javier Fernández-Ruiz
Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington's disease.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Javier Fernández-Ruiz (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Eva de Lago; Miguel Moreno-Martet; Ana Cabranes; José A Ramos; Javier Fernández-Ruiz
Cannabinoids ameliorate disease progression in a model of multiple sclerosis in mice, acting preferentially through CB1 receptor-mediated anti-inflammatory effects.
Neuropharmacology 2012;62(7):2299-308.
2012: Miguel Moreno-Martet; Leyre Mestre; Frida Loría; Carmen Guaza; Javier Fernández-Ruiz; Eva de Lago
Identification of receptors and enzymes for endocannabinoids in NSC-34 cells: relevance for in vitro studies with cannabinoids in motor neuron diseases.
Neuroscience letters 2012;508(2):67-72.
2011: Onintza Sagredo; M Ruth Pazos; Valentina Satta; José A Ramos; Roger G Pertwee; Javier Fernández-Ruiz
Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington's disease.
Journal of neuroscience research 2011;89(9):1509-18.
2011: Javier Fernández-Ruiz; Miguel Moreno-Martet; Carmen Rodríguez-Cueto; Cristina Palomo-Garo; María Gómez-Cañas; Sara Valdeolivas; Carmen Guaza; Julián Romero; Manuel Guzmán; Raphael Mechoulam; et al.
Prospects for cannabinoid therapies in basal ganglia disorders.
British journal of pharmacology 2011;163(7):1365-78.
2011: C García; C Palomo-Garo; M García-Arencibia; Ja Ramos; Rg Pertwee; J Fernández-Ruiz
Symptom-relieving and neuroprotective effects of the phytocannabinoid Δ⁹-THCV in animal models of Parkinson's disease.
British journal of pharmacology 2011;163(7):1495-506.
2011: Agnieszka Jazwa; Ana I Rojo; Nadia G Innamorato; Marlen Hesse; Javier Fernández-Ruiz; Antonio Cuadrado
Pharmacological targeting of the transcription factor Nrf2 at the basal ganglia provides disease modifying therapy for experimental parkinsonism.
Antioxidants & redox signaling 2011;14(12):2347-60.
2011: Cristina Blázquez; Anna Chiarlone; Onintza Sagredo; Tania Aguado; M Ruth Pazos; Eva Resel; Javier Palazuelos; Boris Julien; María Salazar; Christine Börner; et al.
Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease.
Brain : a journal of neurology 2011;134(Pt 1):119-36.
2010: Javier Fernández-Ruiz; Mariluz Hernández; José A Ramos
Cannabinoid-dopamine interaction in the pathophysiology and treatment of CNS disorders.
CNS neuroscience & therapeutics 2010;16(3):e72-91.
2010: Devi Rani Sagar; Maulik D Jhaveri; Denise Richardson; Roy A Gray; Eva de Lago; Javier Fernández-Ruiz; David A Barrett; David A Kendall; Victoria Chapman
Endocannabinoid regulation of spinal nociceptive processing in a model of neuropathic pain.
The European journal of neuroscience 2010;31(8):1414-22.
2010: Javier Fernández-Ruiz; Concepción García; Onintza Sagredo; María Gómez-Ruiz; Eva de Lago
The endocannabinoid system as a target for the treatment of neuronal damage.
Expert opinion on therapeutic targets 2010;14(4):387-404.
2010: Nadia G Innamorato; Agnieszka Jazwa; Ana I Rojo; Concepción García; Javier Fernández-Ruiz; Anna Grochot-Przeczek; Anna Stachurska; Alicja Jozkowicz; Jozef Dulak; Antonio Cuadrado
Different susceptibility to the Parkinson's toxin MPTP in mice lacking the redox master regulator Nrf2 or its target gene heme oxygenase-1.
PloS one 2010;5(7):e11838.
2010: Alexander Kurz; Kay L Double; Isabel Lastres-Becker; Alessandro Tozzi; Michela Tantucci; Vanessa Bockhart; Michael Bonin; Moisés García-Arencibia; Silke Nuber; Falk Schlaudraff; et al.
A53T-alpha-synuclein overexpression impairs dopamine signaling and striatal synaptic plasticity in old mice.
PloS one 2010;5(7):e11464.
2009: Moisés García-Arencibia; Concepción García; Javier Fernández-Ruiz
Cannabinoids and Parkinson's disease.
CNS & neurological disorders drug targets 2009;8(6):432-9.
2009: Eva de Lago; María Gómez-Ruiz; Miguel Moreno-Martet; Javier Fernández-Ruiz
Cannabinoids, multiple sclerosis and neuroprotection.
Expert review of clinical pharmacology 2009;2(6):645-60.
2009: Javier Palazuelos; Tania Aguado; M Ruth Pazos; Boris Julien; Carolina Carrasco; Eva Resel; Onintza Sagredo; Cristina Benito; Julián Romero; Iñigo Azcoitia; et al.
Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity.
Brain : a journal of neurology 2009;132(Pt 11):3152-64.
2009: Onintza Sagredo; Sara González; Ilia Aroyo; María Ruth Pazos; Cristina Benito; Isabel Lastres-Becker; Juan P Romero; Rosa M Tolón; Raphael Mechoulam; Emmanuel Brouillet; et al.
Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: relevance for Huntington's disease.
Glia 2009;57(11):1154-67.
2009: Javier Fernández-Ruiz
The endocannabinoid system as a target for the treatment of motor dysfunction.
British journal of pharmacology 2009;156(7):1029-40.
2009: Marina Rubio; Rosario de Miguel; Javier Fernández-Ruiz; Dolores Gutiérrez-López; Mauro A M Carai; José A Ramos
Effects of a short-term exposure to alcohol in rats on FAAH enzyme and CB1 receptor in different brain areas.
Drug and alcohol dependence 2009;99(1-3):354-8.
2008: María Gómez; Mariluz Hernández; Javier Fernández-Ruiz
Cannabinoid signaling system: does it play a function in cell proliferation and migration, neuritic elongation and guidance and synaptogenesis during brain ontogenesis?
Cell adhesion & migration 2008;2(4):246-8.
2008: Moisés García-Arencibia; Luca Ferraro; Sergio Tanganelli; Javier Fernández-Ruiz
Enhanced striatal glutamate release after the administration of rimonabant to 6-hydroxydopamine-lesioned rats.
Neuroscience letters 2008;438(1):10-3.
2008: M Gómez; M L Hernández; M R Pazos; R M Tolón; J Romero; J Fernández-Ruiz
Colocalization of CB1 receptors with L1 and GAP-43 in forebrain white matter regions during fetal rat brain development: evidence for a role of these receptors in axonal growth and guidance.
Neuroscience 2008;153(3):687-99.
2008: Marina Rubio; Javier Fernández-Ruiz; Rosario de Miguel; Begoña Maestro; J Michael Walker; José A Ramos
CB1 receptor blockade reduces the anxiogenic-like response and ameliorates the neurochemical imbalances associated with alcohol withdrawal in rats.
Neuropharmacology 2008;54(6):976-88.
2008: María Ruth Pazos; Rosa María Tolón; Cristina Benito; Conrado Fernández Rodríguez; Juan José Gorgojo; Manuel Nevado; Mariano Alvarez; Francisco Arias; Francisca Almodóvar; María Teresa Pérez Fernández; et al.
Cannabinoid CB1 receptors are expressed by parietal cells of the human gastric mucosa.
The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 2008;56(5):511-6.
2008: Javier Fernández-Ruiz; María Ruth Pazos; Moisés García-Arencibia; Onintza Sagredo; José A Ramos
Role of CB2 receptors in neuroprotective effects of cannabinoids.
Molecular and cellular endocrinology 2008;286(1-2 Suppl 1):S91-6.
2008: M R Pazos; O Sagredo; J Fernández-Ruiz
The endocannabinoid system in Huntington's disease.
Current pharmaceutical design 2008;14(23):2317-25.
2007: Eva de Lago; Javier Fernández-Ruiz
Cannabinoids and neuroprotection in motor-related disorders.
CNS & neurological disorders drug targets 2007;6(6):377-87.
2007: Onintza Sagredo; Moisés García-Arencibia; Eva de Lago; Simone Finetti; Alessandra Decio; Javier Fernández-Ruiz
Cannabinoids and neuroprotection in basal ganglia disorders.
Molecular neurobiology 2007;36(1):82-91.
2007: Javier Fernández-Ruiz; Manuel Guzmán; José A Ramos
Preface: cannabinoids as new tools for the treatment of neurological disorders.
Molecular neurobiology 2007;36(1):1-2.
2007: Onintza Sagredo; José A Ramos; Alessandra Decio; Raphael Mechoulam; Javier Fernández-Ruiz
Cannabidiol reduced the striatal atrophy caused 3-nitropropionic acid in vivo by mechanisms independent of the activation of cannabinoid, vanilloid TRPV1 and adenosine A2A receptors.
The European journal of neuroscience 2007;26(4):843-51.
2007: Marina Rubio; Douglas McHugh; Javier Fernández-Ruiz; Heather Bradshaw; J Michael Walker
Short-term exposure to alcohol in rats affects brain levels of anandamide, other N-acylethanolamines and 2-arachidonoyl-glycerol.
Neuroscience letters 2007;421(3):270-4.
2007: María Gómez; Mariluz Hernández; Javier Fernández-Ruiz
The activation of cannabinoid receptors during early postnatal development reduces the expression of cell adhesion molecule L1 in the rat brain.
Brain research 2007;1145():48-55.
2007: Moisés García-Arencibia; Sara González; Eva de Lago; José A Ramos; Raphael Mechoulam; Javier Fernández-Ruiz
Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: importance of antioxidant and cannabinoid receptor-independent properties.
Brain research 2007;1134(1):162-70.
2007: Eva de Lago; Silvia Ortega-Gutiérrez; José A Ramos; Maria L López Rodríguez; Javier Fernández-Ruiz
Neurochemical effects of the endocannabinoid uptake inhibitor UCM707 in various rat brain regions.
Life sciences 2007;80(10):979-88.
2007: Javier Fernández-Ruiz; Julián Romero; Guillermo Velasco; Rosa M Tolón; José A Ramos; Manuel Guzmán
Cannabinoid CB2 receptor: a new target for controlling neural cell survival?
Trends in pharmacological sciences 2007;28(1):39-45.
2006: Eva De Lago; Sofia B Gustafsson; Javier Fernández-Ruiz; Jonas Nilsson; Stig O P Jacobsson; Christopher J Fowler
Acyl-based anandamide uptake inhibitors cause rapid toxicity to C6 glioma cells at pharmacologically relevant concentrations.
Journal of neurochemistry 2006;99(2):677-88.
2006: Ana Cabranes; Gareth Pryce; David Baker; Javier Fernández-Ruiz
Changes in CB1 receptors in motor-related brain structures of chronic relapsing experimental allergic encephalomyelitis mice.
Brain research 2006;1107(1):199-205.
2006: Sara González; Camila Scorticati; Moisés García-Arencibia; Rosario de Miguel; José A Ramos; Javier Fernández-Ruiz
Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson's disease.
Brain research 2006;1073-1074():209-19.
2006: Isabel Lastres-Becker; Javier Fernández-Ruiz
An overview of Parkinson's disease and the cannabinoid system and possible benefits of cannabinoid-based treatments.
Current medicinal chemistry 2006;13(30):3705-18.
2006: Onintza Sagredo; José A Ramos; Javier Fernández-Ruiz; María L López Rodríguez; Rosario de Miguel
Chronic Delta9-tetrahydrocannabinol administration affects serotonin levels in the rat frontal cortex.
Naunyn-Schmiedeberg's archives of pharmacology 2006;372(4):313-7.
2006: Eva de Lago; Javier Fernández-Ruiz; Silvia Ortega-Gutiérrez; Ana Cabranes; Gareth Pryce; David Baker; Mariluz López-Rodríguez; José Antonio Ramos
UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disorders.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 2006;16(1):7-18.
2005: Ana Cabranes; Katerina Venderova; Eva de Lago; Filomena Fezza; Antonio Sánchez; Leyre Mestre; Marta Valenti; Antonio García-Merino; José Antonio Ramos; Vincenzo Di Marzo; et al.
Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis.
Neurobiology of disease 2005;20(2):207-17.
2005: Eva de Lago; Paolo Urbani; José Antonio Ramos; Vincenzo Di Marzo; Javier Fernández-Ruiz
Arvanil, a hybrid endocannabinoid and vanilloid compound, behaves as an antihyperkinetic agent in a rat model of Huntington's disease.
Brain research 2005;1050(1-2):210-6.
2005: José Antonio Ramos; Sara González; Onintza Sagredo; María Gómez-Ruiz; Javier Fernández-Ruiz
Therapeutic potential of the endocannabinoid system in the brain.
Mini reviews in medicinal chemistry 2005;5(7):609-17.
2005: Sara González; María Angeles Mena; Isabel Lastres-Becker; Alba Serrano; Justo G de Yébenes; José A Ramos; Javier Fernández-Ruiz
Cannabinoid CB(1) receptors in the basal ganglia and motor response to activation or blockade of these receptors in parkin-null mice.
Brain research 2005;1046(1-2):195-206.
2005: Sara González; Maribel Cebeira; Javier Fernández-Ruiz
Cannabinoid tolerance and dependence: a review of studies in laboratory animals.
Pharmacology, biochemistry, and behavior 2005;81(2):300-18.
2005: Isabel Lastres-Becker; Francisco Molina-Holgado; José A Ramos; Raphael Mechoulam; Javier Fernández-Ruiz
Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease.
Neurobiology of disease 2005;19(1-2):96-107.
2005: J Fernández-Ruiz; S Gonzáles
Cannabinoid control of motor function at the basal ganglia.
Handbook of experimental pharmacology 2005;(168):479-507.
2004: Isabel Lastres-Becker; Nicolas Bizat; Frédéric Boyer; Philippe Hantraye; Javier Fernández-Ruiz; Emmanuel Brouillet
Potential involvement of cannabinoid receptors in 3-nitropropionic acid toxicity in vivo.
Neuroreport 2004;15(15):2375-9.
2004: Joana Gomes-da-Silva; Rosario de Miguel; Javier Fernández-Ruiz; Teresa Summavielle; M Amélia Tavares
Effects of neonatal exposure to methamphetamine: catecholamine levels in brain areas of the developing rat.
Annals of the New York Academy of Sciences 2004;1025():602-11.
2004: Sara González; Marta Valenti; Rosario de Miguel; Filomena Fezza; Javier Fernández-Ruiz; Vincenzo Di Marzo; José A Ramos
Changes in endocannabinoid contents in reward-related brain regions of alcohol-exposed rats, and their possible relevance to alcohol relapse.
British journal of pharmacology 2004;143(4):455-64.
2004: Sara González; Javier Fernández-Ruiz; Vincenzo Di Marzo; Mariluz Hernández; Cristina Arévalo; Cristina Nicanor; Maria Grazia Cascio; Emilio Ambrosio; José A Ramos
Behavioral and molecular changes elicited by acute administration of SR141716 to Delta9-tetrahydrocannabinol-tolerant rats: an experimental model of cannabinoid abstinence.
Drug and alcohol dependence 2004;74(2):159-70.
2004: Eva de Lago; Rosario de Miguel; Isabel Lastres-Becker; José A Ramos; Javier Fernández-Ruiz
Involvement of vanilloid-like receptors in the effects of anandamide on motor behavior and nigrostriatal dopaminergic activity: in vivo and in vitro evidence.
Brain research 2004;1007(1-2):152-9.
2004: João Carlos Sousa; Catarina Grandela; Javier Fernández-Ruiz; Rosário de Miguel; Liliana de Sousa; Ana Isabel Magalhães; Maria João Saraiva; Nuno Sousa; Joana Almeida Palha
Transthyretin is involved in depression-like behaviour and exploratory activity.
Journal of neurochemistry 2004;88(5):1052-8.
2004: Javier Fernández-Ruiz; María Gómez; Mariluz Hernández; Rosario de Miguel; José A Ramos
Cannabinoids and gene expression during brain development.
Neurotoxicity research 2004;6(5):389-401.
2004: I Suárez; G Bodega; M Rubio; J J Fernández-Ruiz; J A Ramos; B Fernández
Prenatal cannabinoid exposure down- regulates glutamate transporter expressions (GLAST and EAAC1) in the rat cerebellum.
Developmental neuroscience 2004;26(1):45-53.
2004: Isabel Suárez; Guillermo Bodega; Javier Fernández-Ruiz; José Antonio Ramos; Miguel Rubio; Benjamín Fernández
Down-regulation of the AMPA glutamate receptor subunits GluR1 and GluR2/3 in the rat cerebellum following pre- and perinatal delta9-tetrahydrocannabinol exposure.
Cerebellum (London, England) 2004;3(2):66-74.
2003: María Gómez; Mariluz Hernández; Björn Johansson; Rosario de Miguel; José Antonio Ramos; Javier Fernández-Ruiz
Prenatal cannabinoid and gene expression for neural adhesion molecule L1 in the fetal rat brain.
Brain research. Developmental brain research 2003;147(1-2):201-7.
2003: I Lastres-Becker; R De Miguel; J J Fernández-Ruiz
The endocannabinoid system and Huntington's disease.
Current drug targets. CNS and neurological disorders 2003;2(5):335-47.
2003: Begoña González; Rosario de Miguel; Sonsoles Martín; Alberto Pérez-Rosado; Julián Romero; Carmen García-Lecumberri; Javier Fernández-Ruiz; José Antonio Ramos; Emilio Ambrosio
Effects of perinatal exposure to delta 9-tetrahydrocannabinol on operant morphine-reinforced behavior.
Pharmacology, biochemistry, and behavior 2003;75(3):577-84.
2003: Sara González; Patricia C Schmid; Javier Fernández-Ruiz; Randy Krebsbach; Harald H O Schmid; José A Ramos
Region-dependent changes in endocannabinoid transmission in the brain of morphine-dependent rats.
Addiction biology 2003;8(2):159-66.
2003: Isabel Lastres-Becker; Nicolas Bizat; Frédéric Boyer; Philippe Hantraye; Emmanuel Brouillet; Javier Fernández-Ruiz
Effects of cannabinoids in the rat model of Huntington's disease generated by an intrastriatal injection of malonate.
Neuroreport 2003;14(6):813-6.
2003: María L López-Rodríguez; Alma Viso; Silvia Ortega-Gutiérrez; Christopher J Fowler; Gunnar Tiger; Eva de Lago; Javier Fernández-Ruiz; José A Ramos
Design, synthesis, and biological evaluation of new inhibitors of the endocannabinoid uptake: comparison with effects on fatty acid amidohydrolase.
Journal of medicinal chemistry 2003;46(8):1512-22.
2003: María L López-Rodríguez; Alma Viso; Silvia Ortega-Gutiérrez; Christopher J Fowler; Gunnar Tiger; Eva de Lago; Javier Fernández-Ruiz; José A Ramos
Design, synthesis and biological evaluation of new endocannabinoid transporter inhibitors.
European journal of medicinal chemistry 2003;38(4):403-12.
2003: Isabel Lastres-Becker; Rosario de Miguel; Luciano De Petrocellis; Alexandros Makriyannis; Vincenzo Di Marzo; Javier Fernández-Ruiz
Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease.
Journal of neurochemistry 2003;84(5):1097-109.
2002: Sara González; Maria Grazia Cascio; Javier Fernández-Ruiz; Filomena Fezza; Vincenzo Di Marzo; José A Ramos
Changes in endocannabinoid contents in the brain of rats chronically exposed to nicotine, ethanol or cocaine.
Brain research 2002;954(1):73-81.
2002: Eva de Lago; Javier Fernández-Ruiz; Silvia Ortega-Gutiérrez; Alma Viso; María Luz López-Rodríguez; José A Ramos
UCM707, a potent and selective inhibitor of endocannabinoid uptake, potentiates hypokinetic and antinociceptive effects of anandamide.
European journal of pharmacology 2002;449(1-2):99-103.
2002: Julián Romero; Isabel Lastres-Becker; Rosario de Miguel; Fernando Berrendero; José A Ramos; Javier Fernández-Ruiz
The endogenous cannabinoid system and the basal ganglia. biochemical, pharmacological, and therapeutic aspects.
Pharmacology & therapeutics 2002;95(2):137-52.
2002: Henrik H Hansen; Iñigo Azcoitia; Sebastián Pons; Julián Romero; Luis Miguel García-Segura; José Antonio Ramos; Harald S Hansen; Javier Fernández-Ruiz
Blockade of cannabinoid CB(1) receptor function protects against in vivo disseminating brain damage following NMDA-induced excitotoxicity.
Journal of neurochemistry 2002;82(1):154-8.
2002: Joana Gomes-da-Silva; Alberto Pérez-Rosado; Rosario de Miguel; Javier Fernández-Ruiz; M Carolina Silva; M Amélia Tavares
Prenatal exposure to methamphetamine in the rat: ontogeny of tyrosine hydroxylase mRNA expression in mesencephalic dopaminergic neurons.
Annals of the New York Academy of Sciences 2002;965():68-77.
2002: Isabel Lastres-Becker; Henrik H Hansen; Fernando Berrendero; Rosario De Miguel; Alberto Pérez-Rosado; Jorge Manzanares; José A Ramos; Javier Fernández-Ruiz
Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease.
Synapse (New York, N.Y.) 2002;44(1):23-35.
2002: I Lastres-Becker; F Berrendero; J J Lucas; E Martín-Aparicio; A Yamamoto; J A Ramos; J J Fernández-Ruiz
Loss of mRNA levels, binding and activation of GTP-binding proteins for cannabinoid CB1 receptors in the basal ganglia of a transgenic model of Huntington's disease.
Brain research 2002;929(2):236-42.
2002: J Fernández-Ruiz; I Lastres-Becker; A Cabranes; S González; J A Ramos
Endocannabinoids and basal ganglia functionality.
Prostaglandins, leukotrienes, and essential fatty acids 2002;66(2-3):257-67.
2002: I Suárez; G Bodega; J J Fernández-Ruiz; J A Ramos; M Rubio; B Fernández
Reduced glial fibrillary acidic protein and glutamine synthetase expression in astrocytes and Bergmann glial cells in the rat cerebellum caused by delta(9)-tetrahydrocannabinol administration during development.
Developmental neuroscience 2002;24(4):300-12.
2001: M L López-Rodríguez; A Viso; S Ortega-Gutiérrez; I Lastres-Becker; S González; J Fernández-Ruiz; J A Ramos
Design, synthesis and biological evaluation of novel arachidonic acid derivatives as highly potent and selective endocannabinoid transporter inhibitors.
Journal of medicinal chemistry 2001;44(26):4505-8.
2001: I Lastres-Becker; M Cebeira; M L de Ceballos; B Y Zeng; P Jenner; J A Ramos; J J Fernández-Ruiz
Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets.
The European journal of neuroscience 2001;14(11):1827-32.
2001: H H Hansen; P C Schmid; P Bittigau; I Lastres-Becker; F Berrendero; J Manzanares; C Ikonomidou; H H Schmid; J J Fernández-Ruiz; H S Hansen
Anandamide, but not 2-arachidonoylglycerol, accumulates during in vivo neurodegeneration.
Journal of neurochemistry 2001;78(6):1415-27.
2001: F Berrendero; A Sánchez; A Cabranes; C Puerta; J A Ramos; A García-Merino; J Fernández-Ruiz
Changes in cannabinoid CB(1) receptors in striatal and cortical regions of rats with experimental allergic encephalomyelitis, an animal model of multiple sclerosis.
Synapse (New York, N.Y.) 2001;41(3):195-202.
2001: I Lastres-Becker; F Fezza; M Cebeira; T Bisogno; J A Ramos; A Milone; J Fernández-Ruiz; V Di Marzo
Changes in endocannabinoid transmission in the basal ganglia in a rat model of Huntington's disease.
Neuroreport 2001;12(10):2125-9.
2000: S González; G Mauriello-Romanazzi; F Berrendero; J A Ramos; M F Franzoni; J Fernández-Ruiz
Decreased cannabinoid CB1 receptor mRNA levels and immunoreactivity in pituitary hyperplasia induced by prolonged exposure to estrogens.
Pituitary 2000;3(4):221-6.
2000: S González; T Bisogno; T Wenger; J Manzanares; A Milone; F Berrendero; V Di Marzo; J A Ramos; J J Fernández-Ruiz
Sex steroid influence on cannabinoid CB(1) receptor mRNA and endocannabinoid levels in the anterior pituitary gland.
Biochemical and biophysical research communications 2000;270(1):260-6.
2000: V Di Marzo; F Berrendero; T Bisogno; S González; P Cavaliere; J Romero; M Cebeira; J A Ramos; J J Fernández-Ruiz
Enhancement of anandamide formation in the limbic forebrain and reduction of endocannabinoid contents in the striatum of delta9-tetrahydrocannabinol-tolerant rats.
Journal of neurochemistry 2000;74(4):1627-35.
2000: A Pérez-Rosado; J Manzanares; J Fernández-Ruiz; J A Ramos
Prenatal Delta(9)-tetrahydrocannabinol exposure modifies proenkephalin gene expression in the fetal rat brain: sex-dependent differences.
Brain research. Developmental brain research 2000;120(1):77-81.
2000: M Hernández; F Berrendero; I Suárez; L García-Gil; M Cebeira; K Mackie; J A Ramos; J Fernández-Ruiz
Cannabinoid CB(1) receptors colocalize with tyrosine hydroxylase in cultured fetal mesencephalic neurons and their activation increases the levels of this enzyme.
Brain research 2000;857(1-2):56-65.
2000: I Suárez; G Bodega; J A Ramos; J J Fernández-Ruiz; B Fernández
Neuronal and astroglial response to pre- and perinatal exposure to delta-9-tetra- hydrocannabinol in the rat substantia nigra.
Developmental neuroscience 2000;22(4):253-63.
2000: J Romero; F Berrendero; A Pérez-Rosado; J Manzanares; A Rojo; J J Fernández-Ruiz; J G de Yebenes; J A Ramos
Unilateral 6-hydroxydopamine lesions of nigrostriatal dopaminergic neurons increased CB1 receptor mRNA levels in the caudate-putamen.
Life sciences 2000;66(6):485-94.
2000: J Fernández-Ruiz; F Berrendero; M L Hernández; J A Ramos
The endogenous cannabinoid system and brain development.
Trends in neurosciences 2000;23(1):14-20.
1999: T Wenger; J J Fernández-Ruiz; J A Ramos
Immunocytochemical demonstration of CB1 cannabinoid receptors in the anterior lobe of the pituitary gland.
Journal of neuroendocrinology 1999;11(11):873-8.
1999: F Berrendero; N Sepe; J A Ramos; V Di Marzo; J J Fernández-Ruiz
Analysis of cannabinoid receptor binding and mRNA expression and endogenous cannabinoid contents in the developing rat brain during late gestation and early postnatal period.
Synapse (New York, N.Y.) 1999;33(3):181-91.
1999: S González; J Manzanares; F Berrendero; T Wenger; J Corchero; T Bisogno; J Romero; J A Fuentes; V Di Marzo; J A Ramos; et al.
Identification of endocannabinoids and cannabinoid CB(1) receptor mRNA in the pituitary gland.
Neuroendocrinology 1999;70(2):137-45.
1999: J Manzanares; J Corchero; J Romero; J J Fernández-Ruiz; J A Ramos; J A Fuentes
Pharmacological and biochemical interactions between opioids and cannabinoids.
Trends in pharmacological sciences 1999;20(7):287-94.
1999: J Romero; F Berrendero; L García-Gil; S Y Lin; A Makriyannis; J A Ramos; J J Fernández-Ruiz
Cannabinoid receptor and WIN-55,212-2-stimulated [35S]GTPgammaS binding and cannabinoid receptor mRNA levels in several brain structures of adult male rats chronically exposed to R-methanandamide.
Neurochemistry international 1999;34(6):473-82.
1999: L García-Gil; J Romero; J A Ramos; J J Fernández-Ruiz
Cannabinoid receptor binding and mRNA levels in several brain regions of adult male and female rats perinatally exposed to delta9-tetrahydrocannabinol.
Drug and alcohol dependence 1999;55(1-2):127-36.
1999: L Garcia-Gil; R de Miguel; J Romero; A Perez; J A Ramos; J J Fernández-Ruiz
Perinatal delta9-tetrahydrocannabinol exposure augmented the magnitude of motor inhibition caused by GABA(B), but not GABA(A), receptor agonists in adult rats.
Neurotoxicology and teratology 1999;21(3):277-83.
1999: J J Fernández-Ruiz; F Berrendero; M L Hernández; J Romero; J A Ramos
Role of endocannabinoids in brain development.
Life sciences 1999;65(6-7):725-36.
1999: S González; J Romero; R de Miguel; I Lastres-Becker; M A Villanua; A Makriyannis; J A Ramos; J J Fernández-Ruiz
Extrapyramidal and neuroendocrine effects of AM404, an inhibitor of the carrier-mediated transport of anandamide.
Life sciences 1999;65(3):327-36.
1998: R de Miguel; J Romero; R M Muñoz; L García-Gil; S González; M A Villanua; A Makriyannis; J A Ramos; J J Fernández-Ruiz
Effects of cannabinoids on prolactin and gonadotrophin secretion: involvement of changes in hypothalamic gamma-aminobutyric acid (GABA) inputs.
Biochemical pharmacology 1998;56(10):1331-8.
1998: J Romero; F Berrendero; J Manzanares; A Pérez; J Corchero; J A Fuentes; J J Fernández-Ruiz; J A Ramos
Time-course of the cannabinoid receptor down-regulation in the adult rat brain caused by repeated exposure to delta9-tetrahydrocannabinol.
Synapse (New York, N.Y.) 1998;30(3):298-308.
1998: J Romero; F Berrendero; L García-Gil; J A Ramos; J J Fernández-Ruiz
Cannabinoid receptor and WIN-55,212-2-stimulated [35S]GTP gamma S binding and cannabinoid receptor mRNA levels in the basal ganglia and the cerebellum of adult male rats chronically exposed to delta 9-tetrahydrocannabinol.
Journal of molecular neuroscience : MN 1998;11(2):109-19.
1998: F Berrendero; J Romero; L García-Gil; I Suarez; P De la Cruz; J A Ramos; J J Fernández-Ruiz
Changes in cannabinoid receptor binding and mRNA levels in several brain regions of aged rats.
Biochimica et biophysica acta 1998;1407(3):205-14.
1998: L García-Gil; J A Ramos; T Rubino; D Parolaro; J J Fernández-Ruiz
Perinatal delta9-tetrahydrocannabinol exposure did not alter dopamine transporter and tyrosine hydroxylase mRNA levels in midbrain dopaminergic neurons of adult male and female rats.
Neurotoxicology and teratology 1998;20(5):549-53.
1998: F Berrendero; L García-Gil; M L Hernández; J Romero; M Cebeira; R de Miguel; J A Ramos; J J Fernández-Ruiz
Localization of mRNA expression and activation of signal transduction mechanisms for cannabinoid receptor in rat brain during fetal development.
Development (Cambridge, England) 1998;125(16):3179-88.
1998: J Romero; F Berrendero; L Garcia-Gil; P de la Cruz; J A Ramos; J J Fernández-Ruiz
Loss of cannabinoid receptor binding and messenger RNA levels and cannabinoid agonist-stimulated [35S]guanylyl-5'O-(thio)-triphosphate binding in the basal ganglia of aged rats.
Neuroscience 1998;84(4):1075-83.
1998: J Romero; J J Fernández-Ruiz; G Vela; M Ruiz-Gayo; J A Fuentes; J A Ramos
Autoradiographic analysis of cannabinoid receptor binding and cannabinoid agonist-stimulated [35S]GTP gamma S binding in morphine-dependent mice.
Drug and alcohol dependence 1998;50(3):241-9.
1998: J Corchero; L García-Gil; J Manzanares; J J Fernández-Ruiz; J A Fuentes; J A Ramos
Perinatal delta9-tetrahydrocannabinol exposure reduces proenkephalin gene expression in the caudate-putamen of adult female rats.
Life sciences 1998;63(10):843-50.
1998: J Romero; T Wenger; R de Miguel; J A Ramos; J J Fernández-Ruiz
Cannabinoid receptor binding did not vary in several hypothalamic nuclei after hypothalamic deafferentation.
Life sciences 1998;63(5):351-6.
1998: J Romero; R de Miguel; J A Ramos; J J Fernández-Ruiz
The activation of cannabinoid receptors in striatonigral GABAergic neurons inhibited GABA uptake.
Life sciences 1998;62(4):351-63.
1997: L García-Gil; R De Miguel; R M Muñoz; M Cebeira; M A Villanua; J A Ramos; J J Fernández-Ruiz
Perinatal delta(9)-tetrahydrocannabinol exposure alters the responsiveness of hypothalamic dopaminergic neurons to dopamine-acting drugs in adult rats.
Neurotoxicology and teratology 1997;19(6):477-87.
1997: J Romero; E Garcia-Palomero; F Berrendero; L Garcia-Gil; M L Hernandez; J A Ramos; J J Fernández-Ruiz
Atypical location of cannabinoid receptors in white matter areas during rat brain development.
Synapse (New York, N.Y.) 1997;26(3):317-23.
1997: J J Fernández-Ruiz; R M Muñoz; J Romero; M A Villanua; A Makriyannis; J A Ramos
Time course of the effects of different cannabimimetics on prolactin and gonadotrophin secretion: evidence for the presence of CB1 receptors in hypothalamic structures and their involvement in the effects of cannabimimetics.
Biochemical pharmacology 1997;53(12):1919-27.
1997: M L Hernández; L García-Gil; F Berrendero; J A Ramos; J J Fernández-Ruiz
delta 9-Tetrahydrocannabinol increases activity of tyrosine hydroxylase in cultured fetal mesencephalic neurons.
Journal of molecular neuroscience : MN 1997;8(2):83-91.
1996: M Navarro; R de Miguel; F Rodríguez de Fonseca; J A Ramos; J J Fernández-Ruiz
Perinatal cannabinoid exposure modifies the sociosexual approach behavior and the mesolimbic dopaminergic activity of adult male rats.
Behavioural brain research 1996;75(1-2):91-8.
1996: J Romero; E García-Palomero; S Y Lin; J A Ramos; A Makriyannis; J J Fernández-Ruiz
Extrapyramidal effects of methanandamide, an analog of anandamide, the endogenous CB1 receptor ligand.
Life sciences 1996;58(15):1249-57.
1995: J Romero; R de Miguel; E García-Palomero; J J Fernández-Ruiz; J A Ramos
Time-course of the effects of anandamide, the putative endogenous cannabinoid receptor ligand, on extrapyramidal function.
Brain research 1995;694(1-2):223-32.
1995: M Guzmán; J J Fernández-Ruiz; C Sánchez; G Velasco; J A Ramos
Effects of anandamide on hepatic fatty acid metabolism.
Biochemical pharmacology 1995;50(6):885-8.
1995: J Romero; L García; J J Fernández-Ruiz; M Cebeira; J A Ramos
Changes in rat brain cannabinoid binding sites after acute or chronic exposure to their endogenous agonist, anandamide, or to delta 9-tetrahydrocannabinol.
Pharmacology, biochemistry, and behavior 1995;51(4):731-7.
1995: G Vela; J A Fuentes; A Bonnin; J Fernández-Ruiz; M Ruiz-Gayo
Perinatal exposure to delta 9-tetrahydrocannabinol (delta 9-THC) leads to changes in opioid-related behavioral patterns in rats.
Brain research 1995;680(1-2):142-7.
1995: A I Martín; J Fernández-Ruiz; A López-Calderón
Effects of catecholamine synthesis inhibitors and adrenergic receptor antagonists on restraint-induced LH release.
The Journal of endocrinology 1995;144(3):511-5.
1995: A Bonnin; R de Miguel; M L Hernández; J A Ramos; J J Fernández-Ruiz
The prenatal exposure to delta 9-tetrahydrocannabinol affects the gene expression and the activity of tyrosine hydroxylase during early brain development.
Life sciences 1995;56(23-24):2177-84.
1995: J Romero; L García; M Cebeira; D Zadrozny; J J Fernández-Ruiz; J A Ramos
The endogenous cannabinoid receptor ligand, anandamide, inhibits the motor behavior: role of nigrostriatal dopaminergic neurons.
Life sciences 1995;56(23-24):2033-40.
1994: A Bonnin; R de Miguel; J J Fernández-Ruiz; M Cebeira; J A Ramos
Possible role of the cytochrome P450-linked monooxygenase system in preventing delta 9-tetrahydrocannabinol-induced stimulation of tuberoinfundibular dopaminergic activity in female rats.
Biochemical pharmacology 1994;48(7):1387-92.
1994: A Bonnin; R de Miguel; J C Rodríguez-Manzaneque; J J Fernández-Ruiz; A Santos; J A Ramos
Changes in tyrosine hydroxylase gene expression in mesencephalic catecholaminergic neurons of immature and adult male rats perinatally exposed to cannabinoids.
Brain research. Developmental brain research 1994;81(1):147-50.
1994: F Rodríguez de Fonseca; M Cebeira; J A Ramos; M Martín; J J Fernández-Ruiz
Cannabinoid receptors in rat brain areas: sexual differences, fluctuations during estrous cycle and changes after gonadectomy and sex steroid replacement.
Life sciences 1994;54(3):159-70.
1994: F Rodríguez de Fonseca; M A Gorriti; J J Fernández-Ruiz; T Palomo; J A Ramos
Downregulation of rat brain cannabinoid binding sites after chronic delta 9-tetrahydrocannabinol treatment.
Pharmacology, biochemistry, and behavior 1994;47(1):33-40.
1994: M Navarro; F Rodríguez de Fonseca; M L Hernández; J A Ramos; J J Fernández-Ruiz
Motor behavior and nigrostriatal dopaminergic activity in adult rats perinatally exposed to cannabinoids.
Pharmacology, biochemistry, and behavior 1994;47(1):47-58.
1994: M L Hernández; J J Fernández-Ruiz; M Navarro; R de Miguel; M Cebeira; L Vaticón; J A Ramos
Modifications of mesolimbic and nigrostriatal dopaminergic activities after intracerebroventricular administration of prolactin.
Journal of neural transmission. General section 1994;96(1):63-79.
1993: M Navarro; J J Fernández-Ruiz; R de Miguel; M L Hernández; M Cebeira; J A Ramos
An acute dose of delta 9-tetrahydrocannabinol affects behavioral and neurochemical indices of mesolimbic dopaminergic activity.
Behavioural brain research 1993;57(1):37-46.
1993: A Bonnin; J A Ramos; F Rodríguez de Fonseca; M Cebeira; J J Fernández-Ruiz
Acute effects of delta 9-tetrahydrocannabinol on tuberoinfundibular dopamine activity, anterior pituitary sensitivity to dopamine and prolactin release vary as a function of estrous cycle.
Neuroendocrinology 1993;58(3):280-6.
1993: M Navarro; J J Fernández-Ruiz; R De Miguel; M L Hernández; M Cebeira; J A Ramos
Motor disturbances induced by an acute dose of delta 9-tetrahydrocannabinol: possible involvement of nigrostriatal dopaminergic alterations.
Pharmacology, biochemistry, and behavior 1993;45(2):291-8.
1993: F Rodríguez de Fonseca; J A Ramos; A Bonnin; J J Fernández-Ruiz
Presence of cannabinoid binding sites in the brain from early postnatal ages.
Neuroreport 1993;4(2):135-8.
1993: A Bonnin; J J Fernández-Ruiz; M Martín; F Rodríguez de Fonseca; M L Hernández; J A Ramos
delta 9-Tetrahydrocannabinol affects mesolimbic dopaminergic activity in the female rat brain: interactions with estrogens.
Journal of neural transmission. General section 1993;92(2-3):81-95.
1992: M Navarro; J J Fernández-Ruiz; F Rodriguez de Fonseca; M L Hernández; M Cebeira; J A Ramos
Modifications of striatal D2 dopaminergic postsynaptic sensitivity during development of morphine tolerance-dependence in mice.
Pharmacology, biochemistry, and behavior 1992;43(2):603-8.
1992: F Rodríguez De Fonseca; J J Fernández-Ruiz; L L Murphy; M Cebeira; R W Steger; A Bartke; J A Ramos
Acute effects of delta-9-tetrahydrocannabinol on dopaminergic activity in several rat brain areas.
Pharmacology, biochemistry, and behavior 1992;42(2):269-75.
1992: F Rodríguez de Fonseca; M L Hernández; R de Miguel; J J Fernández-Ruiz; J A Ramos
Early changes in the development of dopaminergic neurotransmission after maternal exposure to cannabinoids.
Pharmacology, biochemistry, and behavior 1992;41(3):469-74.
1991: F Rodríguez de Fonseca; J J Fernández-Ruiz; L Murphy; J C Eldridge; R W Steger; A Bartke
Effects of delta-9-tetrahydrocannabinol exposure on adrenal medullary function: evidence of an acute effect and development of tolerance in chronic treatments.
Pharmacology, biochemistry, and behavior 1991;40(3):593-8.
1991: M L Hernández; R de Miguel; J A Ramos; J J Fernández-Ruiz
Is prolactin playing a role in the regulation of catecholamine synthesis and release from male rat adrenal medulla?
Journal of endocrinological investigation 1991;14(3):201-8.
1991: F Rodríguez de Fonseca; M Cebeira; J J Fernández-Ruiz; M Navarro; J A Ramos
Effects of pre- and perinatal exposure to hashish extracts on the ontogeny of brain dopaminergic neurons.
Neuroscience 1991;43(2-3):713-23.
1991: J J Fernández-Ruiz; M L Hernández; R de Miguel; J A Ramos
Nigrostriatal and mesolimbic dopaminergic activities were modified throughout the ovarian cycle of female rats.
Journal of neural transmission. General section 1991;85(3):223-9.
1991: M L Hernández; J J Fernández-Ruiz; R de Miguel; J A Ramos
Time-dependent effects of ovarian steroids on tyrosine hydroxylase activity in the limbic forebrain of female rats.
Journal of neural transmission. General section 1991;83(1-2):77-84.
1990: M L Hernández; R de Miguel; J A Ramos; J J Fernández-Ruiz
Prolactin inhibits the activity of tyrosine hydroxylase in cultured bovine adrenal chromaffin cells in a dose-dependent manner.
Brain research 1990;528(1):175-8.
1990: J J Fernández-Ruiz; R de Miguel; M L Hernández; J A Ramos
Time-course of the effects of ovarian steroids on the activity of limbic and striatal dopaminergic neurons in female rat brain.
Pharmacology, biochemistry, and behavior 1990;36(3):603-6.
1990: F Rodriguez de Fonseca; M Cebeira; M L Hernández; J A Ramos; J J Fernández-Ruiz
Changes in brain dopaminergic indices induced by perinatal exposure to cannabinoids in rats.
Brain research. Developmental brain research 1990;51(2):237-40.
1989: J J Fernández-Ruiz; J C Amor; J A Ramos
Time-dependent effects of estradiol and progesterone on the number of striatal dopaminergic D2-receptors.
Brain research 1989;476(2):388-95.
1989: R de Miguel; J J Fernández-Ruiz; M L Hernández; J A Ramos
Role of ovarian steroids on the catecholamine synthesis and release in female rat adrenal: in vivo and in vitro studies.
Life sciences 1989;44(25):1979-86.
1989: J J Fernández-Ruiz; C Alvarez-Sanz; J A Ramos
2-Hydroxyestradiol is not mediating the effects of estradiol on tuberoinfundibular dopaminergic neurons controlling prolactin secretion in female rats.
Journal of steroid biochemistry 1989;32(1A):71-5.
1988: R Cabrera; P Mayor; J Fernández-Ruiz; C Calle
Insulin binding and action on adipocytes from female rats with experimentally induced chronic hyperprolactinemia.
Molecular and cellular endocrinology 1988;58(2-3):167-73.
1988: J J Fernández-Ruiz; C Agrasal; M Cebeira; J A Tresguerres; A I Esquifino; J A Ramos
Effects of estradiol on circulating levels of prolactin in female rats bearing ectopic pituitaries.
Revista española de fisiología 1988;44(2):205-10.
1988: J J Fernández-Ruiz; A R Bukhari; R Martínez-Arrieta; J A Tresguerres; J A Ramos
Effects of estrogens and progesterone on the catecholaminergic activity of the adrenal medulla in female rats.
Life sciences 1988;42(9):1019-28.
1987: A I Esquifino; J J Fernández-Ruiz; M Cebeira; C Agrasal; J A Tresguerres; J A Ramos
Effect of experimentally induced hyperprolactinemia on growth hormone secretion.
Revista española de fisiología 1987;43(4):463-8.
1987: A I Esquifino; C Agrasal; R Steger; J J Fernández-Ruiz; J A Ramos; M Cebeira; A Bartke
Catecholaminergic control of plasma growth hormone and thyrotropin levels in hypophysectomized rats bearing ectopic pituitary transplants.
Life sciences 1987;41(8):1043-50.
1987: J J Fernández-Ruiz; M Cebeira; C Agrasal; J A Tresguerres; A Bartke; A I Esquifino; J A Ramos
Possible role of dopamine and noradrenaline in the regulation of prolactin secretion from an ectopic anterior pituitary gland in female rats.
The Journal of endocrinology 1987;113(1):45-9.
1987: J J Fernández-Ruiz; E Ubeda; M Cebeira; C Agrasal; J A Tresguerres; J A Ramos; A I Esquifino
Modifications of plasma prolactin levels and catecholamine content in an ectopic anterior pituitary gland transplanted under the kidney capsule.
Hormone research 1987;25(2):105-12.